Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Jason Mouabbi, MD
Videos
The Impact of HER2-low Status on Prognosis in Hormone Receptor-Positive Metastatic Breast Cancer Treated With a Targeted Therapy Plus Endocrine Therapy
12/08/2022
Jason Mouabbi, MD, discusses his presentation from the 2022 San Antonio Breast Cancer Symposium on survival outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, finding that HER2-low status may not...
Jason Mouabbi, MD, discusses his presentation from the 2022 San Antonio Breast Cancer Symposium on survival outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, finding that HER2-low status may not...
Jason Mouabbi, MD, discusses his...
12/08/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy
12/07/2022

Katie Herman

Katie Herman
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Conference Coverage
Clinical and Pathological Differences in Breast Cancer Patients With HER2-low and Other Cancer Subtypes
12/07/2022

Katie Herman

Katie Herman
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Dr Joshua Richter, Associate Professor of Medicine, Tisch Cancer Institute
Videos
Analyzing the Effect of Immune Therapies on Infection in Patients With Multiple Myeloma
12/05/2022
Dr Joshua Richter, associate professor of medicine at Tisch Cancer Institute, discusses his presentation on the effects of immune therapies on infection in patients with multiple myeloma.
Dr Joshua Richter, associate professor of medicine at Tisch Cancer Institute, discusses his presentation on the effects of immune therapies on infection in patients with multiple myeloma.
Dr Joshua Richter, associate...
12/05/2022
Journal of Clinical Pathways

Advertisement

OCPC: In Session
Highlights of the 2022 Clinical Pathways Benchmark Survey
12/05/2022
Winston Wong, PharmD, Editor-in-Chief
Winston Wong, PharmD, Editor-in-Chief, presents the highlights of the 2022 Clinical Pathways Benchmark Survey results, as presented as part of the Oncology Clinical Pathways Congress in Boston in October.
Winston Wong, PharmD, Editor-in-Chief, presents the highlights of the 2022 Clinical Pathways Benchmark Survey results, as presented as part of the Oncology Clinical Pathways Congress in Boston in October.
Winston Wong, PharmD,...
12/05/2022
Journal of Clinical Pathways
Matthew Lunning, DO, FACP
Videos
Telehealth Utilization in Clinical Trial Research and Participation
10/27/2022
Matthew Lunning, DO, FACP, discusses the expansion of telehealth during the “COVID era,” highlighting the importance of face-to-face encounters between patients and health care providers, and suggesting ways to successfully meet this demand...
Matthew Lunning, DO, FACP, discusses the expansion of telehealth during the “COVID era,” highlighting the importance of face-to-face encounters between patients and health care providers, and suggesting ways to successfully meet this demand...
Matthew Lunning, DO, FACP,...
10/27/2022
Journal of Clinical Pathways
Ira Klein, MD
Videos
Optimizing Clinical Trials in Academia and Community Oncology
10/27/2022
Ira Klein, MD, discusses design in clinical trials, touching on current issues such as clinical workflow and operational processes, and the barriers to participating in a clinical trial in community oncology.
Ira Klein, MD, discusses design in clinical trials, touching on current issues such as clinical workflow and operational processes, and the barriers to participating in a clinical trial in community oncology.
Ira Klein, MD, discusses design...
10/27/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Optimal Utilization of Telehealth to Enhance Patient Care and Clinical Trial Participation
10/18/2022

Katie Herman and Craig Ostroff

Katie Herman and Craig Ostroff ...
Matthew A Lunning, DO, FACP, Associate Professor, Fred & Pamela Buffett Cancer Center, Associate Vice-Chair of Research Department of Medicine, Assistant Vice Chancellor of Clinical Research, University of Nebraska Medical Center, Omaha,...
Matthew A Lunning, DO, FACP, Associate Professor, Fred & Pamela Buffett Cancer Center, Associate Vice-Chair of Research Department of Medicine, Assistant Vice Chancellor of Clinical Research, University of Nebraska Medical Center, Omaha,...
Matthew A Lunning, DO, FACP,...
10/18/2022
Journal of Clinical Pathways
Conference Coverage
Just in Time Clinical Trials: A Solution for Both Academia and Community Oncology
10/18/2022

Craig Ostroff

Craig Ostroff
At the 2022 Oncology Clinical Pathways Congress, Dr Ira Klein discussed the need to improve access and reach typically underrepresented populations in order to make clinical trials and cancer treatment studies more representative of the...
At the 2022 Oncology Clinical Pathways Congress, Dr Ira Klein discussed the need to improve access and reach typically underrepresented populations in order to make clinical trials and cancer treatment studies more representative of the...
At the 2022 Oncology Clinical...
10/18/2022
Journal of Clinical Pathways
Conference Coverage
CancerLinQ Technology in the Oncology Community
10/17/2022

Katie Herman and Craig Ostroff

Katie Herman and Craig Ostroff ...
Robert S. Miller, MD, FACP, FASCO, FAMIA, Chief Medical Science Officer, CancerLinQ, American Society of Clinical Oncology, described how data aggregation and analytic platforms are aiding in clinical decision support and explained current...
Robert S. Miller, MD, FACP, FASCO, FAMIA, Chief Medical Science Officer, CancerLinQ, American Society of Clinical Oncology, described how data aggregation and analytic platforms are aiding in clinical decision support and explained current...
Robert S. Miller, MD, FACP,...
10/17/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use